JP2015500885A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015500885A5 JP2015500885A5 JP2014548917A JP2014548917A JP2015500885A5 JP 2015500885 A5 JP2015500885 A5 JP 2015500885A5 JP 2014548917 A JP2014548917 A JP 2014548917A JP 2014548917 A JP2014548917 A JP 2014548917A JP 2015500885 A5 JP2015500885 A5 JP 2015500885A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- formula
- heteroalkyl
- aryl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 9
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 8
- 101150113535 chek1 gene Proteins 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 4
- 206010021143 Hypoxia Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 125000003435 aroyl group Chemical group 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 230000007954 hypoxia Effects 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- IAYGCINLNONXHY-LBPRGKRZSA-N 3-(carbamoylamino)-5-(3-fluorophenyl)-N-[(3S)-3-piperidinyl]-2-thiophenecarboxamide Chemical compound NC(=O)NC=1C=C(C=2C=C(F)C=CC=2)SC=1C(=O)N[C@H]1CCCNC1 IAYGCINLNONXHY-LBPRGKRZSA-N 0.000 claims 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 2
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims 2
- SYYBDNPGDKKJDU-ZDUSSCGKSA-N 1-[5-bromo-4-methyl-2-[[(2S)-2-morpholinyl]methoxy]phenyl]-3-(5-methyl-2-pyrazinyl)urea Chemical compound C1=NC(C)=CN=C1NC(=O)NC1=CC(Br)=C(C)C=C1OC[C@H]1OCCNC1 SYYBDNPGDKKJDU-ZDUSSCGKSA-N 0.000 claims 2
- -1 C 1 -C 6 alkyl Chemical group 0.000 claims 2
- YFNWWNRZJGMDBR-LJQANCHMSA-N PF-00477736 Chemical compound C1=NN(C)C=C1C1=NC2=CC(NC(=O)[C@H](N)C3CCCCC3)=CC3=C2C1=CNNC3=O YFNWWNRZJGMDBR-LJQANCHMSA-N 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 230000002950 deficient Effects 0.000 claims 2
- YUCFVHQCAFKDQG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH] YUCFVHQCAFKDQG-UHFFFAOYSA-N 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- GMIZZEXBPRLVIV-SECBINFHSA-N 6-bromo-3-(1-methylpyrazol-4-yl)-5-[(3r)-piperidin-3-yl]pyrazolo[1,5-a]pyrimidin-7-amine Chemical compound C1=NN(C)C=C1C1=C2N=C([C@H]3CNCCC3)C(Br)=C(N)N2N=C1 GMIZZEXBPRLVIV-SECBINFHSA-N 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161579605P | 2011-12-22 | 2011-12-22 | |
| US61/579,605 | 2011-12-22 | ||
| US201261617576P | 2012-03-29 | 2012-03-29 | |
| US61/617,576 | 2012-03-29 | ||
| PCT/US2012/071074 WO2013096687A1 (en) | 2011-12-22 | 2012-12-20 | Administration of hypoxia activated prodrugs in combination with chk1 inhibitors for treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017182053A Division JP2017218459A (ja) | 2011-12-22 | 2017-09-22 | 癌を治療するためのｃｈｋ１阻害剤と組み合わせた低酸素活性化プロドラッグの投与 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015500885A JP2015500885A (ja) | 2015-01-08 |
| JP2015500885A5 true JP2015500885A5 (enExample) | 2016-02-18 |
Family
ID=48669508
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014548917A Pending JP2015500885A (ja) | 2011-12-22 | 2012-12-20 | 癌を治療するためのｃｈｋ１阻害剤と組み合わせた低酸素活性化プロドラッグの投与 |
| JP2017182053A Withdrawn JP2017218459A (ja) | 2011-12-22 | 2017-09-22 | 癌を治療するためのｃｈｋ１阻害剤と組み合わせた低酸素活性化プロドラッグの投与 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017182053A Withdrawn JP2017218459A (ja) | 2011-12-22 | 2017-09-22 | 癌を治療するためのｃｈｋ１阻害剤と組み合わせた低酸素活性化プロドラッグの投与 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US9254299B2 (enExample) |
| EP (1) | EP2793882A4 (enExample) |
| JP (2) | JP2015500885A (enExample) |
| WO (1) | WO2013096687A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160158253A1 (en) | 2013-07-26 | 2016-06-09 | Threshold Pharmaceuticals, Inc. | Treatment of pancreatic cancer with a combination of a hypoxia-activated prodrug and a taxane |
| US10071109B2 (en) | 2013-11-06 | 2018-09-11 | Molecular Templates, Inc. | Predictive biomarker for hypoxia-activated prodrug therapy |
| JP6936007B2 (ja) | 2014-06-17 | 2021-09-15 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ｃｈｋ１阻害剤とａｔｒ阻害剤との組み合わせを使用してがんを処置する方法 |
| EP3313819A1 (en) * | 2015-06-23 | 2018-05-02 | Case Western Reserve University | Compositions and methods for treating cancer |
| WO2018222970A1 (en) * | 2017-06-01 | 2018-12-06 | Sierra Oncology, Inc. | Biomarkers and patient selection strategies |
| KR20220066005A (ko) * | 2019-05-14 | 2022-05-23 | 시에라 온코로지, 인코퍼레이티드 | Chk1 저해제를 사용한 암 치료 방법 |
| JP7762796B2 (ja) | 2021-08-27 | 2025-10-30 | アセンタウィッツ ファーマシューティカルズ リミテッド | Ｐａｒｐ阻害剤に耐性のある患者のｔｈ－３０２による治療 |
| WO2023025291A1 (zh) | 2021-08-27 | 2023-03-02 | 深圳艾欣达伟医药科技有限公司 | 冻干制剂溶液及冻干制剂、方法和用途 |
| CN118829436A (zh) | 2022-03-15 | 2024-10-22 | 深圳艾欣达伟医药科技有限公司 | 治疗brca突变癌症患者的方法 |
| US20250295677A1 (en) | 2022-04-15 | 2025-09-25 | Ascentawits Pharmaceuticals, Ltd. | Method for treating cancer by using th-302 alone or in combination with parp inhibitor |
| WO2023226959A1 (zh) | 2022-05-23 | 2023-11-30 | 深圳艾欣达伟医药科技有限公司 | 烷化剂前药与细胞周期抑制剂联用治疗癌症的方法 |
| WO2024061346A1 (zh) | 2022-09-22 | 2024-03-28 | 深圳艾欣达伟医药科技有限公司 | 乏氧激活的化合物在制备治疗癌症患者的药物中的用途 |
| WO2024179467A1 (zh) | 2023-02-27 | 2024-09-06 | 深圳艾欣达伟医药科技有限公司 | 溶液、冻干制剂、冻干制剂单位包装、注射液及注射液配制方法 |
| AU2024317010A1 (en) | 2023-07-28 | 2026-02-26 | Ascentawits Pharmaceuticals, Ltd. | Treatment of p53 gene mutation or defect negative cancer and tumor patients |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5306727A (en) | 1993-04-30 | 1994-04-26 | Research Corporation Technologies, Inc. | Phosphoramidates useful as antitumor agents |
| US7914994B2 (en) | 1998-12-24 | 2011-03-29 | Cepheid | Method for separating an analyte from a sample |
| GB9909612D0 (en) | 1999-04-26 | 1999-06-23 | Cancer Res Campaign Tech | N-protected amines and their use as prodrugs |
| CA2441228A1 (en) | 2001-03-23 | 2002-10-03 | Aphton Corporation | Combination treatment of pancreatic cancer |
| AU2003217606C1 (en) | 2002-02-21 | 2008-07-17 | Institute Of Virology | Soluble Form of Carbonic Anhydrase IX (s-CA IX), Assays to Detect s-CA IX, CA IXs Coexpression with HER-2/neu/c-erbB-2 and CA IX-Specific Monoclonal Antibodies to Non-Immunodominant Epitopes |
| DE10237931A1 (de) | 2002-08-14 | 2004-02-26 | Endress + Hauser Gmbh + Co. Kg | Vorrichtung zur Überwachung eines vorbestimmten Füllstands eines Messmediums in einem Behälter |
| NZ521851A (en) | 2002-10-08 | 2005-02-25 | Auckland Uniservices Ltd | Nitroaniline-based unsymmetrical mustard alkylating agents for gene dependent enzyme prodrug therapy |
| DK1585749T3 (da) * | 2003-01-09 | 2008-09-22 | Pfizer | Diazepinoindol-derivater som kinaseinhibitorer |
| ZA200507752B (en) | 2003-03-28 | 2007-01-31 | Threshold Pharmaceuticals Inc | Compositions and methods for treating cancer |
| JP4760712B2 (ja) | 2003-10-31 | 2011-08-31 | オークランド ユニサーヴィスィズ リミテッド | 新規ニトロフェニルマスタードおよびニトロフェニルアジリジンアルコールおよびそれらの対応するリン酸エステルおよびターゲットが決められた細胞毒性剤としてのそれらの使用 |
| US7432106B2 (en) | 2004-03-24 | 2008-10-07 | Applied Biosystems Inc. | Liquid processing device including gas trap, and system and method |
| US8545881B2 (en) | 2004-04-19 | 2013-10-01 | Eurand Pharmaceuticals, Ltd. | Orally disintegrating tablets and methods of manufacture |
| EP1743038A4 (en) | 2004-05-04 | 2007-11-21 | Bayer Healthcare | MN / CA IX / CA9 AND KIDNEY CANCER PROGNOSIS |
| US20070117784A1 (en) | 2005-03-04 | 2007-05-24 | Novacea, Inc. | Treatment of hyperproliferative diseases with anthraquinones |
| CN102746336B (zh) | 2005-06-29 | 2015-08-19 | 施瑞修德制药公司 | 氨基磷酸酯烷化剂前体药物 |
| US20090136521A1 (en) | 2005-10-03 | 2009-05-28 | Genetix Pharmaceuticals , Inc. | Method for Selectively Depleting Hypoxic Cells |
| WO2008033041A1 (en) | 2006-09-11 | 2008-03-20 | Auckland Uniservices Limited | Cancer treatment |
| US7807454B2 (en) | 2006-10-18 | 2010-10-05 | The Regents Of The University Of California | Microfluidic magnetophoretic device and methods for using the same |
| EP2114157B1 (en) * | 2006-12-26 | 2021-05-26 | ImmunoGenesis, Inc. | Phosphoramidate alkylator prodrug for the treatment of cancer |
| US8216607B2 (en) | 2008-03-17 | 2012-07-10 | Roger Williams Hospital | Combination of ceramide and gemcitabine for inducing cell death and uses thereof in treating cancer |
| KR101925436B1 (ko) | 2008-04-10 | 2018-12-05 | 버지니아 커먼웰스 유니버시티 | 암 치료를 위한 종양 저 산소 상태의 유도 |
| WO2009139915A2 (en) | 2008-05-15 | 2009-11-19 | The University Of North Carolina At Chapel Hill | Novel targets for regulation of angiogenesis |
| WO2009151598A1 (en) | 2008-06-11 | 2009-12-17 | Genentech, Inc. | Diazacarbazoles and methods of use |
| WO2010048330A1 (en) | 2008-10-21 | 2010-04-29 | Threshold Pharmaceuticals, Inc. | Treatment of cancer using hypoxia activated prodrugs |
| EP2409130B1 (en) | 2009-03-20 | 2013-12-04 | Pbs Biotech, Inc. | Automatable aseptic sample withdrawal system |
| US20120114637A1 (en) | 2009-05-04 | 2012-05-10 | Santen Pharmaceutical Co., Ltd. | Mtor pathway inhibitors for treating ocular disorders |
| MX2012005163A (es) | 2009-11-06 | 2012-11-22 | Infinity Pharmaceuticals Inc | Formulaciones orales de un inhibidor de la ruta de hedgehog. |
| AU2011276590A1 (en) | 2010-06-28 | 2013-01-31 | Threshold Pharmaceuticals, Inc. | Treatment of blood cancer |
| MX2012014428A (es) | 2010-07-12 | 2013-03-05 | Threshold Pharmaceuticals Inc | Administracion de profarmacos activados por hipoxia y de agentes antiangiogenicos para el tratamiento de cancer. |
| US10357577B2 (en) | 2010-07-16 | 2019-07-23 | Auckland Uniservices Limited | Bacterial nitroreductase enzymes and methods relating thereto |
| AU2012236142A1 (en) | 2011-04-01 | 2013-10-17 | Threshold Pharmaceuticals, Inc. | Methods for treating cancer |
| BR112013025969A2 (pt) | 2011-04-15 | 2016-12-20 | Threshold Pharmaceuticals Inc | forma de dose unitária para administração oral |
| JP5805989B2 (ja) | 2011-04-26 | 2015-11-10 | 大塚電子株式会社 | 電気泳動移動度測定用セル並びにそれを用いた測定装置及び測定方法 |
| EP2793899A4 (en) | 2011-12-22 | 2015-06-17 | Threshold Pharmaceuticals Inc | HYPOXIA-ACTIVATED PRODRUGS AND MTOR INHIBITORS FOR CANCER TREATMENT |
| US20150005264A1 (en) | 2012-01-31 | 2015-01-01 | Threshold Pharmaceuticals, Inc. | Predictive biomarker for hypoxia-activated prodrug therapy |
-
2012
- 2012-12-20 EP EP12860951.8A patent/EP2793882A4/en not_active Withdrawn
- 2012-12-20 US US14/367,168 patent/US9254299B2/en not_active Expired - Fee Related
- 2012-12-20 WO PCT/US2012/071074 patent/WO2013096687A1/en not_active Ceased
- 2012-12-20 JP JP2014548917A patent/JP2015500885A/ja active Pending
-
2017
- 2017-09-22 JP JP2017182053A patent/JP2017218459A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015500885A5 (enExample) | ||
| JP2015500884A5 (enExample) | ||
| CY1124117T1 (el) | Ετεροκυκλικες αλκυνυλοβενζολικες ενωσεις και ιατρικες συνθεσεις και χρησεις αυτων | |
| IL275379B2 (en) | Benzylamino-converted pyridopyrimidinones and novel antecedents as sos1 inhibitors | |
| CY1123627T1 (el) | Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου | |
| JP2009502743A5 (enExample) | ||
| WO2015081133A3 (en) | Nucleotides for the treatment of liver cancer | |
| MX2015012432A (es) | Inhibidores piridinicos de la cinasa cdk9. | |
| JP2013518107A5 (enExample) | ||
| WO2013123215A3 (en) | Antiviral drugs for treatment of arenavirus infection | |
| JP2019524883A5 (enExample) | ||
| NZ748966A (en) | Functionalized benzamide derivatives as antiviral agents against hbv infection | |
| FI3377534T3 (fi) | Keuhkosyövän hoito käyttäen anti-pd-1-vasta-aineen ja anti-ctla-4-vasta-aineen yhdistelmää | |
| BRPI0511512A (pt) | derivados pirrolpirimidina úteis no tratamento do cáncer | |
| MX2022013596A (es) | Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico. | |
| WO2008054454A3 (en) | Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents | |
| WO2013004995A8 (en) | Pyrimidinone compounds and their use | |
| JP2015508103A5 (enExample) | ||
| RU2013146659A (ru) | Способы лечения рака | |
| WO2009029622A3 (en) | Antiviral drugs for treatment of arenavirus infection | |
| US10752612B2 (en) | PLK4 inhibitors | |
| MY162319A (en) | Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer | |
| HRP20130959T1 (hr) | Antikancerozni spojevi i farmaceutski pripravci koji ih sadrže | |
| CA2862755A1 (en) | Antiviral compounds with a dibenzooxaheterocycle moiety | |
| MX2009013501A (es) | Compuestos piperidinicos y sus usos. |